JGC
GLUE icon

J. Goldman & Co’s Monte Rosa Therapeutics GLUE Stock Holding History

J. Goldman & Co’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135,000
Closed -$2.12M – 744
2025
Q4 		$2.12M Buy
+135,000
New +$1.82M 0.06% 306

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

J. Goldman & Co's GLUE Position: Q2 2026 in Review

J. Goldman & Co reduced its Monte Rosa Therapeutics (GLUE) stake by 91% in Q2 2026, selling an estimated $2.96M and leaving 15,119 shares worth $366K. The position accounts for 0.01% of the portfolio, ranked #585.

J. Goldman & Co first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.83M in Q1 2026. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • J. Goldman & Co held 15,119 shares of Monte Rosa Therapeutics worth $366K as of Q2 2026.
  • J. Goldman & Co sold 156,652 Monte Rosa Therapeutics shares in Q2 2026, an estimated $2.96M.
  • Monte Rosa Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #585 holding.
  • J. Goldman & Co first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's Monte Rosa Therapeutics position peaked at $2.83M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.